A Multicenter, Phase 3, Open-Label study to Investigate the Efficacy, Pharmacokinetics and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis” Protocol Number I6T-MC-AMB

Project Details

StatusFinished
Effective start/end date8/07/24 → 8/08/24

Funding

  • IQVIA RDS Pty. Limited: A$6,625.00